Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
about
Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-AnalysisNew approaches in the treatment of hepatitis CMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsModulation of host lipid metabolism by hepatitis C virus: Role of new therapiesEmerging therapies for hepatitis CHepatitis C virus: A global viewSofosbuvir/velpatasvir: A promising combinationInterferon therapy in hepatitis C leading to chronic type 1 diabetesAssessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked ParticipantsHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsFour weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.Hepatitis C treatment: where are we now?HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeClinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise reviewBeyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisDaclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyDirect-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionOmbitasvir/Paritaprevir/Ritonavir and Dasabuvir.Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.Impact of hepatitis C status on 20-year mortality of patients with substance use disorders.Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004 to 2012.Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirPopulation Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesShort interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.Hepatitis B and C in pregnancy: a review and recommendations for care.High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and RilpivirineMen with severe hemophilia in the United States: birth cohort analysis of a large national databaseDrug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
P2860
Q26771458-1BD0D59F-2F4B-4FA3-9712-9D7E2B92E62EQ26773271-3CE497EF-76C2-4D76-B74D-3C64F34B6F75Q26773321-B4B8E3DC-EC61-492E-88B2-EC3C6B9D98E2Q26782009-F9B866D9-7845-4C65-B32D-045B6619F572Q26853642-9A2944B1-7997-436B-A617-48E46DF6F1B5Q26862531-501290FE-C5A2-4F0B-BF3E-D8E6C82D1EE2Q27468954-FA2D7715-E12D-47E3-B551-5FEEF8A6D72AQ28080876-A995F109-7435-44FD-82B3-1B8821E62FD4Q28550601-357E1FA8-1541-4070-A4D2-55AE4997CF62Q28652352-FB76922D-BAE8-4C4B-82C2-FABE5E42FBA2Q30368260-479E9E98-713E-4388-B9A3-F39039B92290Q30378509-1AAAFC03-6F01-4AB1-B688-433E55F9AA97Q31012317-C7D796D3-6281-4CB1-AE0E-7E94D2F3F205Q33440436-EDEBF405-2CA7-4455-916B-57BB0E73E6C5Q34424151-FAED5992-8209-4BF4-9E56-570CE95AA70CQ34439125-CCC423DA-1135-4998-BEA8-50072C5A33DDQ34725990-471FC82D-8371-454F-AC30-47B10F630E7AQ34736194-44FB8CCE-417E-4AC2-A483-CB966974CB42Q35023687-7B2D3536-9182-4ED1-B9F4-89274CCCBB7EQ35037688-E9F03C35-A6E8-4D05-80B2-3ABBFA561FCEQ35044909-53B3957B-1254-4792-A061-7659EBB5A258Q35263756-B6CA0944-0B0B-4A95-AFD0-0DDCE6035D1CQ35491398-ECF926CA-DD15-4C5A-AE86-41DA5B699BA5Q35528192-E358EE88-7D76-430A-B02B-A5F92AC87B71Q35592257-96F12A20-645F-4236-BC0F-65579F4E7181Q35905985-A62657CE-6208-4A84-943D-103FF9881C03Q36014286-85020122-C69B-4DB0-91F9-47F62A126588Q36052284-FBA457B3-02B9-4D45-A151-CCD0FDAF7AB6Q36335281-30D7B6C9-5B83-4D45-874B-A4A8A087137DQ36354119-039A1239-69BD-48C3-830F-D2C09CE772F8Q36382409-7A0CAE71-D1A7-436E-9CE4-02B7AF66E648Q36438920-716CDD36-4527-4F99-A6B3-8B5EAE22A6ADQ36445132-12D3AC43-FBEE-4F82-B2B8-58FE3D7EDDEDQ36519135-A6500525-B0E3-4A41-99C5-8483E2D59CB8Q36649138-0E89E2C0-1228-4AED-AD4A-23F5158DF0B8Q36651317-1DA0A57A-C63F-4A52-8F92-A2126C2CFFE8Q36806650-AEFC2BCD-636D-4BD6-903B-9FB180B1839DQ36888008-4F91935E-95E9-4D8D-84F0-8BABAA0A16EAQ37015686-A0FA33C8-15B3-4A48-B223-548499749D89Q37067118-AFED0EAD-8F50-48E4-8700-9949203B0794
P2860
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
@en
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
@nl
type
label
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
@en
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
@nl
prefLabel
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
@en
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
@nl
P2093
P50
P356
P1476
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
@en
P2093
Amit Khatri
Barry Bernstein
Daniel E Cohen
David R Nelson
Eric Lawitz
George Liossis
Graham R Foster
Gregory T Everson
Kris V Kowdley
Lois Larsen
P304
P356
10.1056/NEJMOA1306227
P407
P577
2014-01-01T00:00:00Z